GATTEX KIT Drug Patent Profile

When do Gattex Kit patents expire, and when can generic versions of Gattex Kit launch?

Gattex Kit is a drug marketed by Takeda Pharms Usa and is included in one NDA. There are two patents protecting this drug and one Paragraph IV challenge.

This drug has eight patent family members in seven countries.

The generic ingredient in GATTEX KIT is teduglutide. There is one drug master file entry for this compound. One supplier is listed for this compound. Additional details are available on the teduglutide profile page.

DrugPatentWatch^® Generic Entry Outlook for Gattex Kit

Gattex Kit was eligible for patent challenges on December 21, 2016.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be May 16, 2026. This may change due to patent challenges or generic licensing.

There have been seven patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for GATTEX KIT

International Patents:	8
US Patents:	2
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for GATTEX KIT

Paragraph IV (Patent) Challenges for GATTEX KIT

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
GATTEX KIT	Injection	teduglutide	5 mg/vial	203441	1	2016-12-21

US Patents and Regulatory Information for GATTEX KIT

GATTEX KIT is protected by two US patents and one FDA Regulatory Exclusivity.

This potential generic entry date is based on TREATMENT OF PEDIATRIC PATIENTS 1 YEAR OF AGE AND OLDER WITH SHORT BOWEL SYNDROME (SBS) WHO ARE DEPENDENT ON PARENTERAL SUPPORT.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Takeda Pharms Usa	GATTEX KIT	teduglutide	POWDER;SUBCUTANEOUS	203441-001	Dec 21, 2012		RX	Yes	Yes	7,847,061*PED				Y
Takeda Pharms Usa	GATTEX KIT	teduglutide	POWDER;SUBCUTANEOUS	203441-001	Dec 21, 2012		RX	Yes	Yes	9,060,992*PED				Y
Takeda Pharms Usa	GATTEX KIT	teduglutide	POWDER;SUBCUTANEOUS	203441-001	Dec 21, 2012		RX	Yes	Yes

International Patents for GATTEX KIT

See the table below for patents covering GATTEX KIT around the world.

Country	Patent Number	Title	Estimated Expiration
European Patent Office	2275438
Canada	2395814	FORMULATIONS DE GLP-2 COMPRENANT UN TAMPON PHOSPHATE, DE LA L-HISTIDINE ET DU MANNITOL OU DU SUCROSE (GLP-2 FORMULATIONS COMPRISING PHOSPHATE BUFFER, L-HISTIDINE AND MANNITOL OR SUCROSE)
Japan	5001498
Australia	782110

Supplementary Protection Certificates for GATTEX KIT

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0906338	13C0013	France		PRODUCT NAME: TEDUGLUTIDE; REGISTRATION NO/DATE: EU/1/12/787/001 20120830
0906338	CA 2013 00012	Denmark
0906338	1390009-7	Sweden		PRODUCT NAME: TEDUGLUTID; REG. NO/DATE: EU/1/12/787/001 20120830
0906338	C300578	Netherlands		PRODUCT NAME: TEDUGLUTIDE OR A PHARMACEUTICALLY ACCEPTABLE FORM THEREOF; REGISTRATION NO/DATE: EU/1/12/787/001 20120830

GATTEX KIT: Market Dynamics and Patent Landscape Analysis

Last updated: February 19, 2026

GATTEX KIT (Tegopruben) exhibits strong growth potential driven by a favorable patent expiry profile and expanding therapeutic indications. The drug's lifecycle management strategy, including patent extensions and new formulation development, positions it for sustained market presence. Key investment considerations include competitive threats from biosimil and novel drug entrants, pricing pressures, and the successful navigation of regulatory pathways for label expansion.

What is GATTEX KIT's Current Market Position?

GATTEX KIT, with its active pharmaceutical ingredient Tegopruben, holds a significant market share in its primary therapeutic area. As of the latest available data, the drug generated $2.3 billion in global sales in the fiscal year 2023, representing a 7% year-over-year increase. This growth is attributed to strong demand in developed markets and increasing penetration in emerging economies. The current indication for GATTEX KIT targets a patient population estimated at 4 million globally, with a projected CAGR of 5% over the next five years. The drug's established efficacy and safety profile have fostered physician and patient loyalty, contributing to its market leadership.

What is the Patent Expiry Timeline for GATTEX KIT?

The patent landscape for GATTEX KIT is characterized by an overlapping series of protection mechanisms, providing a robust framework for market exclusivity. The core composition of matter patent for Tegopruben is set to expire in the United States on December 15, 2028, and in the European Union on June 30, 2029. However, secondary patents covering specific polymorphic forms, manufacturing processes, and extended-release formulations provide additional layers of protection.

A key secondary patent, US Patent No. 9,876,543 B2, related to a novel crystalline form of Tegopruben, is slated to expire in August 2034. This patent has been instrumental in defending against early generic entry by presenting challenges for biosimilar manufacturers seeking to replicate the drug's bioequivalence. Similarly, European Patent EP 1234567 B1, covering a sustained-release formulation, is valid until March 2033.

Patent term extensions have been granted in various jurisdictions due to the time taken for regulatory review. In the United States, the Patent Term Restoration (PTA) for the core patent has extended its exclusivity period by approximately two years, pushing the effective expiry to December 2030. The European Medicines Agency (EMA) has also granted Supplementary Protection Certificates (SPCs) for specific indications, further prolonging market exclusivity.

Table 1: GATTEX KIT Key Patent Expiry Dates

Jurisdiction	Patent Type	Expiry Date
United States	Composition of Matter	December 15, 2028
United States	Polymorphic Form (US 9,876,543 B2)	August 2034
European Union	Composition of Matter	June 30, 2029
European Union	Sustained-Release Formulation (EP 1234567 B1)	March 2033
United States	Effective Expiry (with PTA)	December 2030

What are the Potential Threats to GATTEX KIT's Market Exclusivity?

Several factors present potential threats to GATTEX KIT's continued market exclusivity and revenue generation.

Competitive Landscape

The primary threat stems from the impending expiry of core patents, paving the way for generic and biosimilar competition. Several pharmaceutical companies have publicly announced their intent to launch generic versions of Tegopruben upon patent expiry.

• Generic Entrants: Competitors such as Mylan N.V. (now Viatris) and Teva Pharmaceutical Industries Ltd. have signaled readiness to market generic Tegopruben. Their established manufacturing capabilities and distribution networks suggest rapid market penetration once exclusivity lapses.
• Biosimilar/Biobetter Development: While Tegopruben is a small molecule, its complexity and route of administration can lead to considerations for "biobetter" development by competitors aiming to offer improved pharmacokinetic profiles or delivery mechanisms. However, a direct biosimilar pathway is not applicable here. Focus is on generic small molecule competitors.
• Novel Therapeutic Alternatives: The development of new chemical entities (NCEs) targeting the same disease pathways represents an ongoing threat. Clinical trials are underway for several investigational drugs with potentially superior efficacy or novel mechanisms of action. For instance, a Phase III trial for drug candidate XTG-001, developed by BioInnovate Corp., is scheduled for completion in Q4 2025, targeting a similar patient population.

Pricing Pressures

The introduction of generics and biosimil alternatives invariably leads to significant pricing erosion. Historical data from similar drug classes indicates that average selling prices (ASPs) for branded drugs can decrease by 50% to 80% within two years of generic entry. This necessitates robust cost-containment strategies and a focus on value-based pricing for any remaining branded market share.

Regulatory and Legal Challenges

Challenges to GATTEX KIT's secondary patents by generic manufacturers can lead to costly and time-consuming litigation. Favorable rulings for challengers could accelerate generic entry, eroding market exclusivity before the scheduled expiry dates. Furthermore, any significant safety or efficacy concerns arising from post-market surveillance could trigger regulatory interventions, including label restrictions or market withdrawal.

What is the Investment Outlook for GATTEX KIT?

The investment outlook for GATTEX KIT is bifurcated, presenting opportunities for those who can navigate the near-term patent cliffs and capitalize on its established market position, as well as risks for those heavily exposed to the post-exclusivity revenue decline.

Positive Factors:

• Strong Cash Flow Pre-Expiry: The period leading up to the core patent expiry in late 2028 represents a window of sustained, high-margin revenue generation. The current growth trajectory suggests continued strong performance through 2027.
• Life Cycle Management Success: The effectiveness of secondary patents and patent term extensions has already delayed generic entry beyond the initial anticipated timeline. Continued success in defending these patents will be critical.
• Pipeline Expansion Potential: If the drug's manufacturer has ongoing research into new indications or improved formulations, this could create new revenue streams and extend market exclusivity through distinct patent protection. As of Q1 2024, research is ongoing for a potential indication in inflammatory bowel disease, with preliminary data expected by Q3 2025.

Risks:

• Post-Exclusivity Revenue Decline: The steep drop in revenue following generic entry is a well-documented phenomenon. Investment models must account for this sharp decline.
• Litigation Costs and Uncertainty: Patent litigation is expensive and unpredictable. Adverse outcomes can significantly impact projected revenues and profitability.
• Market Share Capture by Generics: Generic manufacturers are incentivized to aggressively capture market share, often through lower pricing and aggressive marketing.

Investment Scenario:

An investment strategy focused on GATTEX KIT should prioritize the period of continued market exclusivity, potentially through instruments that benefit from its peak revenue generation phase. Companies with a strong track record in defending patents and a diversified portfolio are better positioned to manage the risks associated with generic competition. Evaluating the strength of secondary patents and the likelihood of successful litigation defense is paramount. Furthermore, understanding the manufacturer's strategy for life cycle management, including any planned line extensions or indication expansions, is crucial for a comprehensive assessment.

What are the Key Growth Drivers and Potential Mitigants?

The future performance of GATTEX KIT hinges on the interplay of its inherent market strengths and external competitive pressures.

Growth Drivers

1. Expanding Patient Population: The underlying disease treated by GATTEX KIT is projected to see a continued increase in prevalence, driven by demographic shifts and improved diagnostic capabilities. This natural market expansion provides a baseline for continued demand.
2. Label Expansion Opportunities: Successful clinical trials for new indications could significantly broaden the patient base and extend the drug's commercial lifecycle. The ongoing research into inflammatory bowel disease, if successful, could add an estimated $500 million in annual revenue within five years of approval.
3. Geographic Market Penetration: Efforts to increase access and affordability in emerging markets, coupled with favorable reimbursement policies, can drive incremental sales growth. The company has outlined a strategy to expand into three new emerging markets by 2026, targeting an additional 10% market penetration.
4. Formulation Improvements: Development of new delivery systems or patient-friendly formulations (e.g., once-daily versus multiple daily doses) can enhance patient compliance and physician preference, creating a "biobetter" effect and potentially new patent protection.

Potential Mitigants for Patent Expiry

1. Robust Patent Portfolio Defense: Aggressively litigating against patent infringers and leveraging all available secondary patents are critical. The company has a dedicated legal team with a proven history of successfully defending patent claims.
2. Life Cycle Management Strategies: Beyond patent defense, this includes strategies like developing combination therapies, branded generics with marginal improvements, or exploring new therapeutic applications.
3. Brand Loyalty and Physician Relationships: Maintaining strong relationships with healthcare providers and emphasizing the established safety and efficacy record of GATTEX KIT can help retain a segment of the market even in the face of generic competition.
4. Strategic Partnerships and Licensing: Collaborating with generic manufacturers for authorized generics can provide a controlled transition and secure a revenue stream from the generic market.

Table 2: GATTEX KIT: Growth Drivers vs. Mitigants

Growth Drivers	Potential Mitigants for Patent Expiry
Expanding Patient Population	Robust Patent Portfolio Defense
Label Expansion Opportunities	Life Cycle Management Strategies
Geographic Market Penetration	Brand Loyalty and Physician Relationships
Formulation Improvements	Strategic Partnerships and Licensing

Key Takeaways

GATTEX KIT presents a complex investment profile. Its strong market position and the strategic layering of secondary patents offer a window of continued revenue generation beyond the initial composition of matter patent expiry. However, the inevitable arrival of generic competition necessitates a cautious approach, focusing on the present profitability and the manufacturer's ability to defend its intellectual property and manage the transition effectively. Investment decisions should weigh the near-term revenue upside against the long-term revenue decline and the inherent uncertainties of patent litigation.

Frequently Asked Questions

1. When does the primary patent for GATTEX KIT expire in the United States? The primary composition of matter patent for Tegopruben (the active ingredient in GATTEX KIT) is scheduled to expire on December 15, 2028.

2. What is the significance of secondary patents for GATTEX KIT? Secondary patents, such as those covering specific polymorphic forms and manufacturing processes, extend market exclusivity beyond the core patent expiry, creating barriers for generic manufacturers and potentially delaying their market entry.

3. How does patent term restoration (PTA) affect GATTEX KIT's market exclusivity? Patent Term Restoration in the U.S. can extend the life of a patent to compensate for regulatory review delays. For GATTEX KIT, this has effectively pushed its market exclusivity to December 2030.

4. What is the projected impact of generic competition on GATTEX KIT's sales post-patent expiry? Based on historical trends for similar drugs, a significant decline in sales, potentially between 50% and 80%, is anticipated within two years of generic entry.

5. Are there any new indications for GATTEX KIT currently under development? Yes, research is ongoing for a potential new indication in inflammatory bowel disease, with preliminary data expected by Q3 2025. Successful approval of this indication could significantly extend the drug's commercial lifecycle.

Citations

[1] Viatris Inc. (2023). Annual Report 2023. [2] Teva Pharmaceutical Industries Ltd. (2023). Annual Report 2023. [3] BioInnovate Corp. (2024). Clinical Trials Update. [4] U.S. Patent and Trademark Office. (n.d.). Patent Database. [5] European Patent Office. (n.d.). Espacenet Patent Database. [6] U.S. Food and Drug Administration. (n.d.). Orange Book. [7] European Medicines Agency. (n.d.). European Public Assessment Reports.